Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages
Pharmacists discuss the impact and alternatives amid red blood cell shortages in myelofibrosis treatment, highlighting challenges, patient outcomes, quality of life issues, and health care cost implications.
EP: 1.Myelofibrosis Care: Pharmacist Role and Treatment Challenges
EP: 2.Blood Shortages Impacting Myelofibrosis Care
EP: 3.Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages
EP: 4.Impact and Adoption of Momelotinib in Myelofibrosis
EP: 5.Emerging Therapies and Momelotinib Impact
EP: 6.Inpatient to Outpatient: Myelofibrosis Care
EP: 7.Challenges in Outpatient Transition For Myelofibrosis Care
EP: 8.Navigating Myelofibrosis Transitions
EP: 9.Pharmacist-Led Patient Education Strategies
EP: 10.Addressing Socioeconomic Barriers in Myelofibrosis Care
EP: 11.Patient Advocacy in Myelofibrosis Care
EP: 12.Tailoring Myelofibrosis Care: Patient Preferences and Challenges
EP: 13.Advancements in Myelofibrosis Care: Pharmacists' Perspectives
This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.
In this Pharmacy Times® peer exchange, led by Mahmoudjafar, the discussion delves into the challenges of red blood cell transfusion shortages for myelofibrosis patients. Davis highlights issues such as travel, typing delays, and the financial burden associated with transfusions. He provides impactful statistics on increased health care utilization and costs for transfusion-dependent patients.
Nachar suggests alternative treatments, including erythroid-stimulating agents, to mitigate transfusion requirements. Mancini emphasizes the pharmacist’s advocacy role in promoting blood drives to address shortages and discusses the delicate balance in treating anemia and the underlying disease.
This summary offers a concise overview of the profound impact of red blood cell transfusion shortages on myelofibrosis patients, underlining the pharmacist’s crucial role in advocacy and exploring alternative interventions.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
